Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label drug-drug interaction study of migalastat with agalsidase in Fabry disease
2010-022709-16Phase 2Completed
- Sponsor
- Amicus Therapeutics
- Start
- Aug 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of migalastat, agalsidase alfa and agalsidase beta in Fabry disease (FD) (3 arms), sponsored by Amicus Therapeutics. Primary endpoint: AT1001 plasma pharmacokinetic parameter values. Started Aug 2011; status: completed.
02
Drugs
migalastatagalsidase alfaagalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2010-022709-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022709-16.